Income Taxes (Tables)

12 Months Ended

Dec. 31, 2024

Income Tax Contingency [Line Items]

Schedule of Deferred Tax Assets and Liabilities

The Company’s net deferred tax assets (liabilities) are as follows (in thousands):

	Years Ended December 31,
	2024			2023
Deferred tax assets:
Net operating loss carryforwards	$	33,799		$	25,034
Liability to licensor		4,159			4,159
Goodwill		2,683			2,938
Lease liability		176			517
Accrued compensation		556			746
Research credit carryforwards		13,221			10,379
Section 174 cost capitalization		36,951			31,220
Section 59(e) cost capitalization		7,350			8,400
Stock-based compensation		3,938			2,790
Other		5			4
Gross deferred tax assets		102,838			86,187
Less: valuation allowance		(102,655	)		(85,642	)
Total deferred tax assets		183			545
Deferred tax liabilities:
Fixed assets		(75	)		(231	)
Operating lease right-of-use asset		(108	)		(314	)
Total deferred tax liabilities		(183	)		(545	)
Net deferred tax assets	$	—		$	—

Schedule of Unrecognized Tax Benefits

	Years Ended December 31,
	2024		2023
Unrecognized tax benefits - beginning	$	3,602	$	1,968
Gross increases - tax positions in prior period		—		161
Gross increase – current-period tax positions		980		1,473
Unrecognized tax benefits - ending	$	4,582	$	3,602

U.S. Federal Statutory Income Tax Rate [Member]

Income Tax Contingency [Line Items]

Schedule of Unrecognized Tax Benefits

A reconciliation of income tax expense computed at the U.S. federal statutory income tax rate to the Company’s income tax expense is as follows (in thousands):

	Years Ended December 31,
	2024			2023
Tax computed at the federal statutory rate	$	(14,653	)	$	(25,927	)
State income taxes, net of federal tax benefit		(49	)		(8	)
Nondeductible executive compensation		369			99
Stock-based compensation		294			1,326
Research and development and orphan drug credits		(3,789	)		(6,205	)
Uncertain tax positions		947			1,551
Other, net		(132	)		228
Valuation allowance		17,013			28,936
Income tax expense	$	—		$	—